Childhood Astrocytomas Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Childhood Astrocytomas Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Childhood Astrocytomas Treatment (PDQ®)–Health Professional Version

BRAIN CANCER

• Patient
• Health Professional
  • Adult Central Nervous System Tumors Treatment
  • Childhood Brain & Spinal Cord Tumors Treatment
  • Childhood Astrocytomas Treatment
  • Childhood Brain Stem Glioma Treatment
  • Childhood CNS AT/RT Treatment
  • Childhood CNS Embryonal Tumors Treatment
  • Childhood CNS Germ Cell Tumors Treatment
  • Childhood Craniopharyngioma Treatment
  • Childhood Ependymoma Treatment
• Research

SECTIONS

• General Information About Childhood Astrocytomas
• Stage Information for Childhood Astrocytomas
• Treatment Option Overview for Childhood Astrocytomas
• Treatment of Childhood Low-Grade Astrocytomas
• Treatment of Childhood High-Grade Astrocytomas
• Changes to this Summary (01/​27/​2017)
• About This PDQ Summary
• View All Sections

Changes to this Summary (01/27/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Childhood Astrocytomas

Added Becker et al. as reference 31.

Added text to state that because subependymal giant cell astrocytomas are driven by mammalian target of rapamycin (mTOR) activation, mTOR inhibitors are active agents that can induce tumor regression in children with these tumors (cited Franz et al. as reference 45).

The High-grade gliomas subsection was extensively revised.

Added text about the prognostic significance of molecular subtypes in pediatric glioblastoma multiforme (cited Korshunov et al. as reference 53).

Treatment of Childhood Low-Grade Astrocytomas

Added text to state that in a study of patients who were treated with everolimus for 5 years, a reduction in the size of the mass was observed in about 50% of cases; in many cases, the reduction was sustained. These patients also had a reduction in seizure frequency (cited Franz et al. as reference 65).

Added text to state that early results on the use of the BRAF V600E inhibitor dabrafenib, presented in abstract, demonstrated a 41% overall response rate by central review in children with BRAF V600–mutant relapsed or refractory low-grade gliomas (cited Kieran et al. as reference 81).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Treatment of Childhood High-Grade Astrocytomas

Next section >
About This PDQ Summary

• Updated: January 27, 2017